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Abstract: The discovery of antimicrobials as β-lactam antibiotics or aminoglycosides revolutionized the treatment
of infectious diseases. However, the extensive use rapidly created the problem of resistant pathogens, which
are increasingly difficult to treat. FimH antagonists are a new class of antimicrobials, which target the bacterial
adhesion to urothelial cells, a crucial first step in the establishment of urinary tract infections. Because of their
different mode of action, FimH antagonists neither kill nor inhibit the growth of bacteria, they should have a
reduced potential to generate resistant strains. This mini-review outlines the main problems associated with
increasing development of antimicrobial resistance. Furthermore, it summarizes the currently available in vivo
studies in mice for the treatment of urinary tract infections conducted with FimH antagonists.
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1. Antibiotics and Resistance – The
Microbiological Twins
The discovery of β-lactame antibiot-
ics in the 1930s as well as the introduction
of hygienic standards in hospitals (hand
washing, use of disinfectants) was an in-
cisive step in the development of public
healthcare. Humans gained control over a
10
7
times smaller organism and the mortal-
ity from bacterial infections rapidly dimin-
ished and concomitantly also the interest
to develop new antimicrobials. However,
shortly after it was assumed that bacte-
rial infections were under control, the first
emergence of resistant strains evolved. The
ability of our tiny cohabitants to adapt to
new living conditions was severely under-
rated and only insufficient efforts were un-
dertaken to contain the emerging bacterial
threat with new antibiotics.
[1]
Therefore,
since the 1990s, infectious diseases have
non-surprisingly developed to become one
of the top five causes of death in high-in-
come countries.
[2]
The majority of the classes of antimi-
crobials still used today have their origin
in the 1940s to 1970s (Fig. 1).
[3]
Although
numerous chemically modified deriva-
tives entered the market in recent years,
real innovation only occurred in the last
10 years when new classes of antibiotics
were approved for clinical use (oxazolidi-
nones, lipopeptides and mutilins).
[4,11]
The
diminished interest to develop new antibi-
otics and the rapidly increasing emergence
of resistance led to the highly prevalent
problem that for an increasing number of
multidrug-resistant (MDR) and pandrug-
resistant (PDR) bacteria no effective thera-
peutic treatment is available.
[4]
An essential
cause for the emergence of antimicrobial
resistance is the extensive use of antibiot-
ics, leading to treatment failure, a reduced
range of therapeutic options for consecu-
tive bacterial infections and ultimately a
serious threat for the patient.
[12,13]
The most common bacterial infectious
diseases are respiratory tract infections and
urinary tract infections (UTIs). Although
UTI is not a life-threatening disease, all
symptomatic infections should be treated
with antibiotics to prevent potential dev-
astating complications, like pyelonephritis
and urosepsis. Thus, the availability of a
novel class of antimicrobials based on an
alternative mode of action would have
a huge impact on the treatment of UTI,
being a substantial contribution to public
health.
[14]
2. Adhesion and Infection – The
Importance of the FimH Lectin for
UTIs
The crucial step for the majority of
infectious diseases is the initial contact
(adhesion) of the infecting microorgan-
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Fig. 1. Timeline of the major steps of the development of antibiotics (top
[4]
) and the FimH anti-
adhesion therapy for the treatment of UTI (bottom
[5–10]
).
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peritoneally two and three days after the
infection with the bacteria/antagonist mix-
ture, leading to no significant supplemen-
tal benefit. As mentioned by Sharon and
coworkers,
[7]
a major drawback of the UTI
mouse model is the spontaneous clearance
of bacteria from the urinary tract 14 days
after infection (up to 45%). Nevertheless,
when the sampling of urine was conducted
for up to 16 days, a significant reduction of
bacteriuric mice treated with the FimH an-
tagonist compared to the control group was
observed. Based on this promising in vivo
experiment, research directed to the iden-
tification of improved FimH antagonists
[27]
as well as the elucidation of the underlying
mechanisms of this host-pathogen interac-
tion (e.g. type 1 and P-pili,
[28]
phase varia-
tion of type 1 pili,
[29]
immune response,
[30]
etc.) was initiated.
In the 1980s, Svanborg Edén et al.
[8]
repeated the in vivo study
[7]
with methyl
α-d-mannopyranoside (1) by instilling a
higher concentration of bacteria/antago-
nist mixture into the bladder of mice. 2
and 16 h after the onset of infection, the
animals were sacrificed to analyze their
bladder and kidneys for bacterial counts.
Surprisingly, they reported no reduction of
bacterial load, although they used a higher
ism with the target cells, enabling bacteria
to avoid the natural clearing mechanisms
and the immune system and thereby en-
sure survival in the host environment.
[14]
UTI is predominantly caused by uropha-
thogenic Escherichia coli (UPEC) and
strongly depends on the specific adhesion
of the pathogen to carbohydrate-contain-
ing ligands on the host endothelium.
[15]
The ability of UPEC to adhere to and to
ascend within the urinary tract is mediated
via filamentous multi-subunit membrane
proteins, so-called type 1 pili and P-pili.
[16]
Whereas P-pili account for the infection
of the kidneys (pyelonephritis), type 1 pili
are responsible for the initial colonization
of the bladder (cystitis). The four subunits
FimA, FimF, FimG and FimH compose a
type 1pilus,withFimH located at the tip.
[17]
As a part of the FimH subunit, a carbo-
hydrate-recognition domain (CRD) is re-
sponsible for bacterial attachment to oligo-
mannosides of the glycoprotein uroplakin
Ia (UPIa) located on the urinary bladder
mucosa.
[18]
This initial step prevents the
rapid clearance of E. coli from the urinary
tract by the bulk flow of urine and at the
same time, initiates the infection process
(Fig. 2A).
[19]
3. Virulence and FimH – A Target
for Anti-Adhesion Therapy
Previous studies clearly demonstrated
that type 1 pili deficient UPEC strains are
not able to initiate an infection in mice.
[21]
Furthermore, the immunization of mice
with antibodies directed against FimH,
protected animals from bladder-coloniza-
tion with UPEC.
[22]
These findings strong-
ly suggest that the inhibition of the initial
host-pathogen interaction with FimH an-
tagonists as a suitable approach to prevent
and treat UTIs.
The host defense system exerts a FimH
related mechanism to protect the sterile
urinary tract from invading UPECs. The
most abundant protein in the urine is the
Tamm-Horsfall protein (THP; also called
uromodulin). It is a high-mannosylated
glycoprotein and is exclusively produced
in the kidneys. It is able to neutralizeUPEC
by binding to their type 1 pili and it thereby
prevents the adhesion to urothelial cells.
[23]
Interestingly, it is highly conserved dur-
ing evolution and THP-deficient mice are
more susceptible to UTI.
[24]
Once the bac-
teria are trapped by THP, the THP/bacteria
cluster is eliminated by the urine flow from
the urinary tract. FimH antagonists would
support the host defense mechanism to
clear excessively invading bacteria. In ad-
dition, type 1 pili exhibit several important
target-qualities for the development of an
anti-adhesion therapy: (i) they are the most
prevalent fimbriae encoded by UPEC, (ii)
they are highly conserved during evolution
and (iii) they mediate the adhesion, which
is the first and most important step for
the establishment of the infection cycle
(Fig. 2).
4. UTI Mouse Model and Treatment
– The Therapeutic Potential of
FimH Antagonists
4.1 Initial in vivo Studies
In the 1970s, Sharon and coworkers
pioneered the discovery of anti-adhesion
molecules targeting FimH. They reported
on the in vitro inhibitory potential of meth-
ylα-d-mannopyranoside (1)
[25]
(Fig. 3)and
p-nitrophenyl α-d-mannopyranoside,
[26]
and investigated (in vitro and in vivo) the
FimH lectin as a potential target for an anti-
adhesion therapy. In the first in vivo proof
of concept study, FimH antagonist 1 was
pre-incubated with type 1 pili expressing
UPEC strains and the mixture was instilled
transurethrally into the bladder of mice.
[7]
Urine samples were analyzed every two to
three days for bacterial counts, resulting in
a significant reduction of bacteriuric mice
after 5–16 days. In a second experiment,
an additional dose of 1 was injected intra-
uropathogenic
E. coli
urothelial cells
1.
2.
3.
4.
5.
UPIa
type 1 pili
A
B
FimH antagonist
Fig. 2. A) Urinary tract infection cycle. 1. The first and most important step in the development
of UTI is the type 1 pili dependent adhesion of UPEC to uroplakin Ia (UPIa) on urothelial cells. 2.
Adhesion triggers the invasion of the bacteria into the superficial bladder cells, lining the urinary
tract. Once inside the cells, bacteria start to replicate and form 3. intracellular biofilms, where
they are well protected from the host defense mechanisms and antibiotic treatment. 4. Later on,
cells start to exfoliate and bacteria exit the cells in filamentous structures and 5. disperse in the
environment ready to infect new cells (infection cycle adapted from ref. [20]). B) In the presence of
FimH antagonists, UPECs are not able to adhere to urothelial cells and are therefore washed out
with the flow of urine. As a result, the infection cycle cannot be established.
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Fig. 3. α-d-Mannopyranosides tested in the UTI mouse model. Methyl and n-heptyl α-d-
mannopyranosides 1a and 1b,
[7–9]
biphenyl α-d-mannopyranoside 2a and 2b,
[9]
diamidobiphenyl
α-d-mannopyranoside 3a and 3b
[10]
and monoamidobiphenyl α-d-mannopyranoside 4.
[10]
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day clearly indicate the potential of orally
available FimH antagonists for the preven-
tion and treatment of UTIs, with a higher
therapeutic effect compared to treatment
with antibiotics.
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inoculation concentration of 1 compared
to the in vivo experiment of Sharon and
coworkers
[7]
(5 mg/ml vs. 0.1 mg/ml). The
different outcome of the two in vivo ex-
periments could be related to the applied
bacterial strains. Both groups used clini-
cal UPEC isolates for their in vivo stud-
ies, however, Svanborg Edén et al.
[8]
sub-
jected their strain to chemical mutagenesis
by treatment with N-methyl-N-nitro-N-
nitrosoguanidine, leading to randommuta-
tions.
[31]
Modified binding properties could
therefore explain the different outcome of
the two in vivo experiments. Furthermore,
methyl α-d-mannopyranoside (1) is a low
affinity antagonist
[32]
and would probably
require much higher concentrations for the
high level of inoculation (up to 10
9
UPECs
per mouse,
[8]
compared to 10
6
UPECs by
Sharon and coworkers
[7]
).
After these initial in vivo studies inves-
tigating the therapeutic potential of FimH
antagonists,
[7,8]
no further in vivo studies
were published for almost three decades
(Fig. 1). At the same time, however, the
UTImousemodel was extensively used for
in depth investigations of the basic mech-
anisms of bacteria associated UTIs.
[16]
Simultaneously, the development of more
potent FimH antagonists followed two ma-
jor directions. First, multivalent FimH an-
tagonists were investigated
[33]
and second,
based on structural information obtained
from the crystal structure of FimH co-crys-
tallized with antagonists,
[34]
monovalent,
high-affinity antagonists were designed
[27]
(the design, synthesis and in vitro evalua-
tion of mono- and oligovalent mannosides
is reviewed in detail by Hartmann and
Lindhorst,
[27]
and Ernst and Magnani
[35]
).
4.2 Orally Available FimH
Antagonists
Recently, Klein et al.
[9]
published for
the first time in vitro and in vivo pharma-
cokinetic (PK) data of monovalend FimH
antagonists. For oral availability, an opti-
mal balance between solubility, perme-
ability and lipophilicity is required. In
addition, to ensure the availability of the
antagonist at the target organ (bladder), a
prodrug approach was applied. The ester
2a is orally absorbed and hydrolyzed to the
renally excretable acid 2b. When applied
to the UTI mouse model (single dose of 50
mg/kg, p.o.) ten minutes prior to infection,
a substantial reduction of colony forming
units (up to –4 log
10
CFU) in the bladder
could be detected.
In a recent study by Cusumano et al.
[10]
the FimH antagonists were evaluated for
their potential to treat as well as to prevent
UTI inmice. For this purpose, animalswith
a two-week chronic infection were treated
with 3a (single dose 100 mg/kg p.o.) or 3b
and 4 (single dose of 50 mg/kg p.o.), re-
sulting in an 3 log
10
CFU reduction of blad-
der counts for 3a and up to –4 log
10
CFU
for 3b and 4 six hours after treatment. In
comparison, the antibiotic trimethoprim-
sulfamethoxazole (TMP-SMZ, applied in
the drinking water) only reduced bacterial
counts by 1.5 log
10
CFU. Furthermore, an-
tagonists applied together with antibiotics
were reported to have a synergistic effect
on the treatment outcome. In a 24 hours
multiple dosage study (3 times 50 mg/kg
of 4, every eight hours) for the treatment of
chronic infections, bacterial counts in the
bladder were reduced by –4.5 log
10
CFU.
Furthermore, to prevent infection, a single
dose of 3a (50 mg/kg) was applied 30 min-
utes prior to infection, resulting in a –1.5
log
10
CFU reduction of bladder counts, 6 h
after infection. Additionally, these authors
reported that treatment with FimH antago-
nists prevented invasion of UPECs into the
bladder cells leading to a reduction of bio-
film formation.
In summary, both studies confirmed the
promising potential of orally applied FimH
antagonists for both prevention and treat-
ment of UTIs in vivo. In addition, FimH
antagonists proved to be equally effective
as antibiotics. Whereas in the initial treat-
ment experiments
[7,8]
bacteria/antagonist
mixtures were directly applied into the
bladder, the latter studies
[9,10]
used a thera-
peutically more relevant protocol by ap-
plying the FimH antagonists either p.o. or
i.v., which closer simulates conditions used
for later patient application. Furthermore,
the higher potency of the newly developed
FimH antagonists, further contributed to
the positive therapeutic outcome in theUTI
mouse model. However, the orally applied
antagonists (2a, 3a, 3b & 4) still exhibit
unfavorable PK properties (e.g. low solu-
bility, short exposure in plasma and urine),
which both research teams aim to improve
with further investigations.
5. Summary and Outlook
Although the development of resistant
bacteria started shortly after the introduc-
tion of the first antimicrobial drugs,
[13]
the
treatment paradigm only recently shifted
from killing the pathogen to inhibiting
its adhesion to the host cells. The anti-
adhesion therapy is focusing on the devel-
opment of a new class of antimicrobials
exhibiting less selection pressure and
therefore a reduced potential for the emer-
gence of resistance. In addition, a reduc-
tion of the antibiotic associated side effects
(e.g. the disruption of the commensal mi-
crobiota) is expected. A recent very prom-
ising example is the inhibition of the type 1
pili dependent adhesion of uropathogenic
Escherichia coli (UPEC) to bladder cells
for the treatment of urinary tract infections
(UTIs). The in vivo studies reported to this
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